Imperial Innovations notes that its portfolio company, Veryan Medical, a specialist in vascular disease, has announced the completion of four major milestones in its MIMICS clinical programme:
- publication of an article on the MIMICS study;
- the enrolment of the 200th patient in the MIMICS-2 IDE study;
- the first live case transmission from a US MIMICS-2 investigational site; and
- the start of the MIMICS-3D registry.
An article entitled Helical Centerline Stent Improves Patency: Two-Year Results From the Randomized MIMICS Trial was published in the latest issue of Circulation: Cardiovascular Interventions, authored by Professor Thomas Zeller MD, Professor Peter Gaines MD, Gary Ansel, MD and Professor Colin Caro. The Mimics trial is the first randomised trial that compared two bare-metal stents to treat symptomatic disease of the superficial femoral and popliteal arteries and demonstrated that stent design influences clinical outcome. Use of the BioMimics 3D helical stent resulted in higher patency at 2 years when compared with a straight stent. This study is the first demonstration of the benefits of the BioMimics stent design, which when implanted imparts natural curvature to the diseased artery, promoting swirling blood flow to improve the outcome of peripheral intervention.
Veryan has also announced that the 200th patient has been enrolled into the MIMICS-2 study. MIMICS-2 is a prospective, single-arm, multicentre clinical study of 280 patients at more than 40 investigational sites in the US, Germany and Japan.
Further details of these and other milestones are available on Veryan's website.